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Variants of the transforming growth factor-beta receptor type 1 (TGFBR1) gene, TGFBR1*6A and Int7G24A, have been suggested to
act as low-penetrance tumour susceptibility alleles with TGFBR1*6A being causally responsible for some cases of familial colorectal
cancer (CRC). We performed a case–control study of 262 unrelated familial CRC cases; 83 hereditary non-polyposis colorectal
cancer (HNPCC) and 179 non-HNPCC. Patients were genotyped for TGFBR1*6A and Int7G24A and compared with 856 controls.
Further, we screened the coding region of TGFBR1 in affected members of a large family with CRC linked to 9q22.32-31.1.
TGFBR1*6A allelic frequency was not significantly different in all of the familial cases compared with controls (0.107 and 0.106,
respectively; P¼0.915). In a subgroup analysis allele frequencies were, however, different between HNPCC and non-HNPCC familial
cases (0.157 and 0.084, respectively; P¼0.013). TGFBR1*6A genotype did not influence age of onset. Int7G24A allele frequencies
were similar in cases and controls. No germ-line mutation was identified in the family with CRC linked to this chromosomal region.
Our study provides no substantial support for the hypothesis that the polymorphic variants TGFBR1*6A or Int7G24A contribute to
familial CRC risk. We cannot, however, exclude the possibility that TGFBR1 variants have a modifying effect on inherited risk per se.
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Colorectal cancer (CRC) is the third most common cause of
cancer-related mortality in the Western countries, and in the
United States it represents the second most common cause of
cancer mortality (Parkin, 2001). Although 35% of all CRC seems to
involve an inherited susceptibility (Lichtenstein et al, 2000).
Mendelian predisposition syndromes associated with mutations in
known genes (such as APC, DNA mismatch repair genes (MMR),
MYH, SMAD4, BMPR1A/ALK3 and STK11/LKB1) collectively only
account for 5% of disease burden (Lichtenstein et al, 2000; Lynch
and de la Chapelle, 2003). The nature of the remaining heritability
is undefined, but a model in which part of the inherited risk is
conferred by common, low-penetrance alleles seems highly
probable and has been the rationale for seeking to identify disease
alleles through association analyses.
Transforming growth factor-b (TGF-b) is a potent inhibitor of
cell growth influencing the behaviour of a number of cancers
(Derynck et al, 2001). The TGF-b mediates its action through a
heteromeric cell-surface complex of two types of transmembrane
serine/threonine kinases, TGF-b receptor type 1 (TGFBR1) and
type 2 (TGFBR2) (Lin et al, 1992; Ebner et al, 1993). The TGFBR2
gene is mutated in several cancer types with B90% of colon
cancers characterized by MMR deficiency displaying frameshift
mutations in a polyadenine tract of TGFBR2, which encodes the
signal peptide of the expressed protein (Parsons et al, 1995).
A relatively common variant of the TGFBR1 gene, TGFBR1*6A,
is caused by deletion of three GCG triplets coding for alanine
within a nine alanine (*9A) repeat sequence of exon 1, reportedly
associated with less TGF-b growth inhibitory signalling capacity
than the native expressed protein (Chen et al, 1999; Pasche et al,
1999). In some epidemiological studies, the TGFBR1*6A allele has
been reported to be associated with an increased risk of a number
of different malignancies, including CRC (Pasche et al, 1999; Chen
et al, 2001; Baxter et al, 2002; Kaklamani and Pasche, 2005).
In addition, the TGFBR1*6A variant has been proposed to be
directly causally responsible for a proportion of hereditary non-
polyposis colorectal cancer (HNPCC), especially those without
MMR deficiency (Bian et al, 2005). Intriguingly, TGFBR1 maps to
chromosome 9q22.32-31.1, a from several independent studies
suggested CRC susceptibility locus (Wiesner et al, 2003; Kemp
et al, 2006; Skoglund et al, 2006).
Another polymorphic variant of TGFBR1, Int7G24A, has also
been implicated in cancer susceptibility, associations with kidney,
bladder, breast and non-small cell lung cancer being reported
(Chen et al, 1999, 2004; Zhang et al, 2003).
To further evaluate the relationship between the TGFBR1
variants and CRC risk we determined whether these variants
contribute to familial CRC. Using a case–control design, we
compared TGFBR1*6A and Int7G24A allele frequencies in HNPCC
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sand non-HNPCC familial CRC cases with population-based
controls. We also examined whether germ-line TGFBR1 mutations
are responsible for the CRC susceptibility locus on chromosome 9
by screening the entire coding region of TGFBR1 in affected
members of a large family with adenoma and CRC linked to
chromosome 9q22.32-31.1 (Skoglund et al, 2006).
MATERIALS AND METHODS
Study population
Two hundred and sixty-two families, ascertained through the
Family Cancer Clinic at Karolinska University Hospital,
Stockholm, Sweden during 1990–2006, were included in the study.
A total of 83 families, all with a germ-line mutation in one of the
MMR genes, were considered as HNPCC and 179 families were
diagnosed and counselled as non-HNPCC according to our earlier
published protocol (Lagerstedt Robinson et al, 2007). From each
family one case was selected for case–control studies. The
selection was made using the following priority order; (1) proband
(when affected), (2) youngest CRC case or (3) youngest case with
adenoma. Statistical analysis was carried out on CRC plus
adenoma cases and CRC cases alone. Epidemiological studies have
shown that a personal history of colon adenomas places one at
increased risk of developing CRC (Neugut et al, 1993; Jacobson
and Neugut, 1996; Liljegren et al, 2003). Furthermore, adenomas
are over-represented in CRC families and first-degree relatives of
patients with large adenomas are at increased risk of developing
CRCs or large adenomas (Lindgren et al, 2002; Cottet et al, 2007).
Removal of adenomatous polyps is associated with reduced CRC
incidence (Muller and Sonnenberg, 1995; Winawer et al, 2000).
Eight hundred and fifty-six blood donors from the Karolinska
University Hospital, Stockholm, Sweden served as source of
control DNA.
For mutation screening of TGFBR1, we analysed genomic DNA
from a family with CRC and adenoma linked to chromosome
9q22.32-31.1. A full description of this family has been published
earlier (Skoglund et al, 2006).
The study was undertaken in accordance with the Swedish
legislation of ethical permission (2003:460) and the Stockholm
regional ethical committee (Dnr: 2000/291, 2005/566) in accor-
dance with the Declaration of Helsinki.
Genotyping
The TGFBR1*6A variant was determined by PCR amplification
using fluorescently labelled primers Fwd- 50-GAGGCGAG
GTTTGCTGGGGTGAGG-30 and Rev- 50-CATGTTTGAGAAAGAGC
AGGAGCG-30. Amplification was performed using the Platinum-
Taq DNA polymerase and supplied protocol for GC-rich fragments
(Invitrogen, Carlsbad, CA, USA). Amplified fragments were
separated by electrophoresis on an ABI 377 semi-automated
DNA Sequencer (Applied Biosystems, Bedford, MA, USA) and
genotypes assigned using GENESCAN and GENOTYPER software
(Applied Biosystems). A product size of 256bp corresponded to
the most common allele, *9A, whereas a product size of 247bp
corresponded to the *6A allele. Besides the *9A and *6A alleles, we
observed three rare alleles (Figure 1). The *5A/*9A genotype was
detected in one non-HNPCC case and one control case. Another
two individuals with a *7A/*9A genotype and one individual with a
*9A/*10A genotype was detected, all in the control group. All these
rare alleles have been reported earlier (Pasche et al, 1999; Spillman
et al, 2005). All *6A homozygotes and *6A/*9A heterozygotes and
all samples with rare alleles were retyped after a second
independent PCR amplification to confirm the allele calling.
Genotyping of the Int7G24A variant was performed by PCR
amplification of intron 7 using primers Fwd- 50-GGAGGTTCATC
CAAATATGGC-30 and Rev- 50-CTCTGGCACTCGGTGACAT-30
followed by Bsr1 digestion and visualisation on a 2.5% agarose
gel (Figure 2). For 85 samples, restriction enzyme digestion was
replicated after a second independent PCR amplification to
confirm the allele calling. Further details on genotyping can be
obtained from the authors.
Mutation screening of TGFBR1
Mutational analysis of TGFBR1 was conducted on germ-line DNA
from affected individuals in family 24 carrying the linked
haplotype using a combination of denaturing high performance
liquid chromatography (dHPLC) (exons 2–9þ1091bp upstream
of exon 1) and direct sequencing (exon 1þ30UTR). Details on
family 24 have been published earlier (Skoglund et al, 2006).
Owing to stringent surveillance only one individual alive (Co-166)
had developed CRC. Individual Co-166 was mutation screened for
all fragments. The selection of additional individuals for mutation
screening was carried out based on carrier status of the linked
haplotype along with grade of affected status.
Screening for genomic deletions and rearrangements was
performed using reverse transcriptase–PCR. RNA from two
affected individuals (Co-186 and Co-213) plus two controls was
extracted with the Qiagen RNeasy kit (Operon Biotechnologies,
Huntsville, AL, USA) and reverse-transcribed with a first-strand
synthesis kit (Amersham Biosciences, Piscataway, NJ, USA).
Primer sequences and details of all the assays are available on
request.
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Figure 1 Representative electropherograms of the *9A/*9A, *6A/*9A,
*6A/*6A, *5A/*9A, *7A/*9A and *9A/*10A genotypes. Allele and size in
base pairs are indicated below each peak.
Bsr1
Figure 2 Genomic sequence surrounding the Int7G24A variant and a
representative photograph of the PCR-RFLP analysis. The variant site is
marked in bold and the Bsr1 recognition site is underlined. Bsr1 recognises
and cuts the wild-type sequence (smaller band) whereas the variant
abolishes the Bsr1 restriction site (larger band).
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Risks associated with TGFBR1 genotypes were estimated by odds
ratios (ORs) using unconditional logistic regression, and asso-
ciated 95% confidence intervals (CIs) were computed. To test for
population stratification the distribution of genotypes were tested
for a departure from Hardy–Weinberg equilibrium. Differences in
the distribution of continuous variables were compared using
Mann–Whitney U-test or the statistics of Cuzick (1985) and
Altman (1991) and between proportions by Fisher’s exact test.
Confidence limits for sequence changes among cases were
computed under the assumption that frequencies followed a Poisson
distribution. All statistical analyses were performed using STATA
Version 7.0 (Stata Corporation, College Station, TX, USA). A P-value
of 0.05 was considered statistically significant in all analyses.
RESULTS
The characteristics of the study participants are detailed in Table 1.
Cases from HNPCC families were diagnosed with CRC younger
than those from non-HNPCC families (45 years vs 57 years,
respectively; Po0.01) consistent with ascertainment selection.
The observed frequencies of TGFBR1*6A genotypes in cases and
controls were in accordance with Hardy–Weinberg laws of
equilibrium (P¼0.35 and 1.00 in familial non-HNPCC and
HNPCC cases; P¼0.86 in controls), providing no evidence of
population stratification within the dataset. The frequency of
TGFBR1*6A was not significantly different between controls
(0.106, 95% CI: 0.102–0.135) and all familial cases (0.107, 95%
CI: 0.082–0.137; Table 2A). Confining the affection status to a
diagnosis of CRC only and excluding adenomas did not change the
results much (0.117, 95% CI: 0.087–0.151; Table 2B).
Eighty-three of the cases had HNPCC and 179 had non-HNPCC
hereditary CRC. Among those with non-HNPCC; 26 (14.5%) and
two (1.1%) were hetero- and homozygous for the TGFBR1*6A
allele, respectively (TGFBR1*6A allele frequency 0.084). Of the 83
cases with HNPCC; 22 (26.5%) and two (2.4%) were TGFBR1*6A
heterozygotes and homozygotes, respectively (TGFBR1*6A allele
frequency 0.157). Of the 24 TGFBR1*6A carriers; 10 had a MLH1
mutation, 11 had a MSH2 mutation and three had a MSH6
mutation. Although the frequency of the TGFBR1*6A allele was
similar in non-HNPCC familial cases and controls (0.084 and
0.106, respectively; P¼0.23), the frequency in HNPCC cases was
markedly elevated (0.157; P¼0.045) compared with the controls.
Hence, there was an apparent difference in TGFBR1*6A allele
frequency between HNPCC and non-HNPCC familial cases (0.157
and 0.084, respectively; P¼0.013). Table 2A details the ORs of
CRC and adenoma and corresponding 95% CIs associated with
TGFBR1*6A hetero- and homozygosity in the two familial CRC
groups. When performing test for association restricting affection
Table 1 Demographics and clinical status of HNPCC and non-HNPCC
familial colorectal cancer cases
HNPCC (n¼83) Non-HNPCC (n¼179)
Characteristics No. (%) of patients No. (%) of patients
Age
Mean (s.d.), years 45 (11) 57 (11)
Range, years 22–76 28–84
Sex
Male 46 (55) 78 (44)
Female 37 (45) 101 (56)
Clinical manifestation
CRC 82 (99) 132 (74)
Adenoma 1 (1) 47 (26)
Fulfillment of Guidelines
a
Amsterdam criteria I 42 (56) 17 (9)
Amsterdam criteria II 53 (71) 19 (11)
Bethesda Guidelines 73 (97) 140 (78)
MMR gene mutation
MLH1 40 (48) —
MSH2 35 (42) —
MSH6 8 (10) —
Abbreviations: CRC¼colorectal cancer; HNPCC¼hereditary non-polyposis color-
ectal cancer; MMR¼mismatch repair.
aFor a definition of the Amsterdam criteria I,
see Vasen et al (1991); extended Amsterdam II criteria, see Vasen et al (1999);
Bethesda guidelines, see Rodriguez-Bigas et al (1997) and Umar et al (2004).
Table 2A Association between TGFBR1*6A genotypes and risk of colorectal cancer and adenoma
Controls n¼856
a
All familial cases n¼262
a Non-HNPCC n¼179
a HNPCC n¼83
Exon 1Genotype No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
9A/9A 682 (79.7) 209 (79.8) 1.0 150 (83.8) 1.0 59 (71.1) 1.0
9A/6A 160 (18.7) 48 (18.3) 0.98 (0.68–1.40) 26 (14.5) 0.74 (0.47–1.16) 22 (26.5) 1.59 (0.95–2.67)
6A/6A 10 (1.2) 4 (1.5) 1.31 (0.41–4.21) 2 (1.1) 0.91 (0.20–4.19) 2 (2.4) 2.30 (0.50–10.8)
9A/6A and 6A/6A 170 (19.9) 52 (19.8) 1.00 (0.71–1.41) 28 (15.6) 0.75 (0.48–1.16) 24 (28.9) 1.63 (0.99–2.70)
6A frequency 0.106 0.107 0.084 0.157
Abbreviation: HNPCC¼hereditary non-polyposis colorectal cancer.
aIncluded in the total number are rare TGFBR1 alleles such as *5A, *7A, *8A, *10A, *11A and *12A.
Table 2B Association between TGFBR1*6A genotypes and risk of colorectal cancer
Controls n¼856
a
All familial cases n¼214
a Non-HNPCC n¼132
a HNPCC n¼82
Exon 1 Genotype No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
9A/9A 682 (79.7) 167 (78.0) 1.0 109 (83.2) 1.0 58 (70.7) 1.0
9A/6A 160 (18.7) 42 (19.6) 1.07 (0.73–1.57) 20 (15.2) 0.78 (0.47–1.30) 22 (26.8) 1.62 (0.96–2.72)
6A/6A 10 (1.2) 4 (1.9) 1.63 (0.51–5.27) 2 (1.5) 1.25 (0.27–5.79) 2 (2.4) 2.35 (0.50–11.0)
9A/6A and 6A/6A 170 (19.9) 46 (21.3) 1.11 (0.77–1.60) 22 (16.7) 0.81 (0.50–1.32) 24 (29.2) 1.66 (1.00–2.75)
6A frequency 0.106 0.117 0.091 0.159
Abbreviation: HNPCC¼hereditary non-polyposis colorectal cancer.
aIncluded in the total number are rare TGFBR1 alleles such as *5A, *7A, *8A, *10A, *11A and *12A.
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corresponding ORs were similar (Table 2B).
To further explore the possibility that carrier status might affect
CRC risk we compared the age of onset of CRC in TGFBR1*6A
carriers and non-carriers. There was no association between age at
diagnosis of CRC and TGFBR1*6A genotype (data not shown).
Comparison of the cumulative distribution curves also showed no
significant difference in carriers compared with non-carriers.
Among familial non-HNPCC cases the average age at cancer
diagnosis in TGFBR1*6A carriers and non-carriers was 58.4 years
(s.d., 13.0) and 56.8 years (s.d., 10.6), respectively. Corresponding
ages at diagnosis in carriers and non-carriers in HNPCC cases was
43.3 years (s.d., 11.0) and 45.7 years (s.d., 10.6), respectively.
In the study by Bian et al (2005), the highest TGFBR1*6A
frequency was found among MMR mutation-negative cases with
MSI-negative tumours. Data on tumour DNA samples evaluated
for MSI status were available from 249 of the cases. Among all
familial cases, TGFBR1*6A carrier frequency was not significantly
different in MSI-positive cases compared with MSI negative
(P¼0.17). Among HNPCC cases with MSI tumours (MMR/MSI
positive) over-representation of TGFBR1*6A carriers was evident,
albeit non-significantly compared with the controls (data not
shown). Subdividing the whole sample set by Amsterdam criteria
and MMR status showed the highest TGFBR1*6A allelic frequency
in Amsterdam criteria-positive families with a detected MMR gene
mutation (0.198). On the contrary, the allelic frequency was zero in
Amsterdam criteria-negative families with no detected MMR
mutation.
The Int7G24A variant was successfully genotyped in 262 familial
CRC cases, 179 non-HNPCC and 83 HNPCC, and 853 controls. The
observed frequencies of Int7G24A genotypes in cases and controls
were in accordance with Hardy–Weinberg laws of equilibrium
(P¼1.00 and 0.09 in familial non-HNPCC and HNPCC cases;
P¼0.82 in controls). There were no differences in allele or
genotype frequencies between cases and controls or between the
different types of familial CRC (Tables 3A and 3B).
In an earlier study, we have shown linkage of CRC and colorectal
adenomas to chromosome 9q22.32-31.1 in a large Swedish family
(family 24) (Skoglund et al, 2006). To exclude the possibility that
sequence variation in TGFBR1 is responsible for the linkage in the
family, we screened for germ-line mutations in affected family
members. The TGFBR1*6A and Int7G24A variants were not on the
linked haplotype. Two individuals (Co-213 and Co-219) were
heterozyogous TGFBR1*6A carriers. The remaining seven indivi-
duals with the linked haplotype were *9A homozygous. For the
Int7G24A variant; the two individuals screened for this fragment
(Co-166 and Co-648) were not carriers of this variant. No sequence
change was detected on the linked haplotype.
DISCUSSION
Some studies have reported an over-representation of TGFBR1*6A
in individuals with a number of different cancers fuelling
speculation by Pasche et al (2004) that the TGFBR1*6A allele
represents a low-penetrance allele with pleiotropic effects. The
same research group reported a case–control study comparing
TGFBR1*6A allelic frequency among HNPCC patients subdivided
by first MMR gene mutations status and second tumour MSI
status, observing a markedly elevated frequency of TGFBR1*6A
carriers among MMR gene mutation-negative cases with the
highest frequency among cases with MSI-negative tumours (Bian
et al, 2005). On this basis they postulated that the TGFBR1*6A
allele may be causally responsible for a proportion of non-HNPCC
occurrence.
In contrast to Bian et al (2005) in our study TGFBR1*6A allelic
frequency was not significantly different in all of the familial cases
compared with controls. Moreover, in a subgroup analysis (which
inevitably invokes the issue of multiple testing and apparent
paradoxes) allele frequencies were only significantly different in
HNPCC cases with a known MMR genetic defect, indicating a
possible role if any as a modifying factor in HNPCC families.
Further subdivision by MMR- and MSI status confirms this
observation however, groups are small and differences were not
significant. Further studies are needed to confirm this observation.
In our study, 48 cases affected with adenomas were included in
the analysis. However, as shown in Table 2b excluding these did
not change the results indicating that the TGFBR1*6A variant
confers the same increased risk for adenoma as for CRC in these
families.
The intronic variant, Int7G24A, has been variously associated
with an increased risk of kidney-, bladder- and breast cancer
Table 3A Association between Int7G24A genotypes and risk of colorectal cancer and adenoma
Controls n¼853
All familial cases n¼262 Non-HNPCC n¼179 HNPCC n¼83
Int7G24A Genotype No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
G/G 559 (65.5) 165 (63.0) 1.0 110 (61.4) 1.0 55 (66.3) 1.0
G/A 265 (31.1) 83 (31.7) 1.06 (0.79–1.44) 61 (34.1) 1.17 (0.83–1.65) 22 (26.5) 0.84 (0.50–1.41)
A/A 29 (3.4) 14 (5.3) 1.64 (0.84–3.17) 8 (4.5) 1.40 (0.62–3.15) 6 (7.2) 2.10 (0.84–5.29)
G/A and A/A 294 (34.5) 97 (37.0) 1.12 (0.84–1.49) 69 (38.5) 1.19 (0.86–1.66) 28 (33.7) 0.97 (0.60–1.56)
A frequency 0.189 0.212 0.215 0.205
Abbreviation: HNPCC¼hereditary non-polyposis colorectal cancer.
Table 3B Association between Int7G24A genotypes and risk of colorectal cancer
Controls n¼853
All familial cases n¼214 Non-HNPCC n¼132 HNPCC n¼82
Int7G24A Genotype No. of cases (%) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI) No. of cases (%) OR (95% CI)
G/G 559 (65.5) 135 (63.1) 1.0 80 (60.6) 1.0 55 (67.1) 1.0
G/A 265 (31.1) 67 (31.3) 1.05 (0.76–1.45) 46 (34.8) 1.21 (0.82–1.79) 21 (25.6) 0.81 (0.48–1.36)
A/A 29 (3.4) 12 (5.6) 1.71 (0.85–3.45) 6 (4.5) 1.45 (0.58–3.59) 6 (7.3) 2.10 (0.84–5.29)
G/A and A/A 294 (34.5) 79 (36.9) 1.11 (0.82–1.52) 52 (39.4) 1.24 (0.85–1.80) 27 (32.9) 0.93 (0.58–1.51)
A frequency 0.189 0.213 0.220 0.201
Abbreviation: HNPCC¼hereditary non-polyposis colorectal cancer.
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smaller control dataset than that used for evaluation of
TGFBR1*6A, we found no real evidence that Int7G24A influences
CRC risk.
The pivotal role TGFBR1 plays in tumour development makes
the hypothesis that germ-line variation in the gene may influence
CRC susceptibility an attractive concept. A recent study has
reported that germ-line allele-specific expression (ASE) of TGFBR1
is a quantitative trait detectable in 10–20% of CRC patients and
1–3% of the population (Valle et al, 2008). Moreover it was
proposed ASE is dominantly inherited trait, if confirmed these
findings are compatible for this association being responsible for
450% of the excess familial risk of CRC. Paradoxically, although
two major TGFBR1 haplotypes were predominant among ASE
cases (one of the two major haplotypes included TGFBR1*6A and
overall 50% of ASE cases carried the TGFBR1*6A variant) no
causal variant was identified.
In contrast to the findings of Valle et al (2008) in a large case–
control study and meta-analysis of eight earlier published studies of
the relationship between TGFBR1*6A and CRC, we found little
evidence for the tenet that germ-line variation in the gene defined by
this variant significantly influences CRC risk (Skoglund et al, 2007).
For this study, we had 262 families available for analysis. On the
basis of published estimations of sample size needed for achieving
adequate power to detect association our data set has limited
power. However, analysing familial cases provide a means of
generating a genetically enriched dataset with increased power
to show associations compared with using unselected cases
(Houlston and Peto, 2003). Without appropriate adjustment,
however, derived genotypic risks computed are inflated, hence
the upper confidence limits of the risk of CRC associated with the
variants in our study will be overoptimistic.
As source of controls, we have employed blood donors. No data,
because of policy of anonymity, was available for age, ethnicity,
medical- or family history for these individuals. However, it is
unlikely that this will have significantly influenced study findings
as any age or gender difference from controls will be minimal.
Furthermore, although the ethnicity data on blood donors was not
available these individuals were drawn from the same demographic
region as the cases analysed making the probability of confound-
ing from population stratification unlikely. Blood donors con-
stitute a healthy cohort with a risk for later onset diseases, such as
CRC close to that of the general population. Still, even if the
controls are representative for the general population, cases
included are not consecutive but constitute a cohort genetically
enriched for risk alleles. Therefore, we used OR rather than the
relative risk to calculate the risk associated with the variants.
Mutational analysis of TGFBR1 in the earlier published family 24
with CRC and adenoma linked to chromosome 9q22.32-31.1
(Skoglund et al, 2006) showed no sequence changes on the linked
haplotype. Furthermore, the linked haplotype carried the normal
sequence for the two studied variants, TGFBR1*6A and Int7G24A.
Therefore, we can exclude these variants as disease causing in this
family. This is in accordance with two recent studies where the
TGFBR1*6A variant was investigated in a sample linked to this
locus and excluded as the disease-causing variant (Kemp et al,
2006; Daley et al, 2007). The fact that the linked haplotype carried
the normal sequence for the two studied variants TGFBR1*6A and
Int7G24A means it is therefore different from at least one of the
TGFBR1 ASE haplotypes reported by Valle et al (2008) which
carried the TGFBR1*6A variant.
We cannot exclude the possibility that variants of TGFBR1 are
associated with a small CRC risk modifying the impact of other
gene effects. However, on the basis of our findings it seems
unlikely that variation in TGFBR1 defined by the TGFBR1*6A
and the Int7G24A makes a significant contribution to familial
CRC risk.
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